TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the company’s stock with a “Buy” rating and a price objective of $110, as reported by The Fly. The firm highlighted VYKAT XR as the first-approved treatment for hyperphagia in Prader-Willi syndrome (PWS). As per the firm, the drug bucked the trend of clinical shortcomings in PWS by securing the regulatory approval.

TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy

A clinical-stage biopharmaceutical company’s boardroom, emphasizing the importance of decision-making for the lead candidate development of a once-daily oral tablet.

The firm demonstrated confidence in Soleno Therapeutics, Inc. (NASDAQ:SLNO)’s management team, mentioning that they seem to be prepared to execute a strong launch with a high price tag and sizable population to itself. The analysis exhibits that the company has positioned itself for commercial success. The firm remains optimistic and believes that the PWS community’s urgency is expected to drive significant uptake of VYKAT XR, reflecting robust demand potential among patients and caregivers.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) also announced that its Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and children aged 4 years and older with PWS, who possess hyperphagia, had been validated by the EMA (European Medicines Agency). TimesSquare Capital Management, an equity investment management company, released its Q1 2025 investor letter. Here is what the fund said:

“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases. The FDA granted approval of Vyvkat for treating Prader Willi syndrome, a rare genetic disorder that causes life-threatening obesity in children. That development served to boost the stock price by 60% and we decided to book some of the profits by cutting back on the investment.”

While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.